Soleno Therapeutics’ Vykat XR, the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome, has exceeded expectations in its initial full-quarter sales, with net revenues projected between $31 million and $33 million for Q2 2025. The drug’s uptake has been driven by demand from physicians and patients, with over 600 patient starts initiated. Despite initial investor skepticism, the launch has attracted renewed market interest, supporting a recent $200 million capital raise to further fund commercial activities and development.